Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases

Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases

Background The efficacy of anti‐programmed cell death‐1/ligand 1 antibody monotherapy (anti‐PD‐1/PD‐L1 monotherapy) in patients with active brain metastases (BMs) is not established. Here, we aimed to evaluate the efficacy of anti‐PD‐1/PD‐L1 monotherapy in non‐small cell lung cancer (NSCLC) patients...

Full description

Bibliographic Details
Main Authors: Takehiro Tozuka, Satoru Kitazono, Hiroaki Sakamoto, Hiroshi Yoshida, Yoshiaki Amino, Shinya Uematsu, Takahiro Yoshizawa, Tsukasa Hasegawa, Ryo Ariyasu, Ken Uchibori, Noriko Yanagitani, Takeshi Horai, Masahiro Seike, Akihiko Gemma, Makoto Nishio
Format: Article
Language:English
Published: Wiley 2020-09-01
Series:Thoracic Cancer
Subjects:
Anti PD‐1/PD‐L1 antibody
brain metastases
central nervous system metastases
immune checkpoint inhibitor
Online Access:https://doi.org/10.1111/1759-7714.13557

Internet

https://doi.org/10.1111/1759-7714.13557

Similar Items